Global Primary Biliary Cholangitis Therapeutics Market 2024-2028

The primary biliary cholangitis therapeutics market is forecasted to grow by USD 346.85 mn during 2023-2028, accelerating at a CAGR of 8.75% during the forecast period. The report on the primary biliary cholangitis therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by emergence of telehealth and remote monitoring, rising investments and developments in healthcare industry, and increase in product launches in primary biliary cholangitis therapeutics market.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	8%
CAGR	8.75%
Incremental Value	$346.85mn

Technavio's primary biliary cholangitis therapeutics market is segmented as below:

By Type

Primary drug
Secondary drug

By Distribution Channel

Drug stores and retail pharmacies
Hospital pharmacies
Online pharmacies

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increasing demand for R&D due to government healthcare expenditure as one of the prime reasons driving the primary biliary cholangitis therapeutics market growth during the next few years. Also, increasing geriatric population and rise in the R and D investments in primary biliary cholangitis therapeutics by manufacturers will lead to sizable demand in the market.

The report on the primary biliary cholangitis therapeutics market covers the following areas:

Primary biliary cholangitis therapeutics market sizing
Primary biliary cholangitis therapeutics market forecast
Primary biliary cholangitis therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading primary biliary cholangitis therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Ltd., Eli Lilly and Co., GENFIT SA, Glenmark Pharmaceuticals Ltd., ICE S.p.a., Intercept Pharmaceuticals Inc., Ipsen Pharma, Leeford Healthcare Ltd., NGM Biopharmaceuticals Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Lifesciences Ltd.. Also, the primary biliary cholangitis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR76783

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global primary biliary cholangitis therapeutics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global primary biliary cholangitis therapeutics market 2018 - 2022 ($ million)
4.2 Type Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
4.3 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Type

6.1 Market segments
Exhibit 30: Chart on Type - Market share 2023-2028 (%)
Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 Primary drug - Market size and forecast 2023-2028
Exhibit 34: Chart on Primary drug - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Primary drug - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Primary drug - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Primary drug - Year-over-year growth 2023-2028 (%)
6.4 Secondary drug - Market size and forecast 2023-2028
Exhibit 38: Chart on Secondary drug - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Secondary drug - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Secondary drug - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Secondary drug - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Type
Exhibit 42: Market opportunity by Type ($ million)
Exhibit 43: Data Table on Market opportunity by Type ($ million)

7 Market Segmentation by Distribution Channel

7.1 Market segments
Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 46: Chart on Comparison by Distribution Channel
Exhibit 47: Data Table on Comparison by Distribution Channel
7.3 Drug stores and retail pharmacies - Market size and forecast 2023-2028
Exhibit 48: Chart on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 49: Data Table on Drug stores and retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 50: Chart on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Drug stores and retail pharmacies - Year-over-year growth 2023-2028 (%)
7.4 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 60: Market opportunity by Distribution Channel ($ million)
Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Canada - Market size and forecast 2023-2028
Exhibit 87: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 China - Market size and forecast 2023-2028
Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
9.11 UK - Market size and forecast 2023-2028
Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 111: Abbott Laboratories - Overview
Exhibit 112: Abbott Laboratories - Business segments
Exhibit 113: Abbott Laboratories - Key news
Exhibit 114: Abbott Laboratories - Key offerings
Exhibit 115: Abbott Laboratories - Segment focus
12.4 AbbVie Inc.
Exhibit 116: AbbVie Inc. - Overview
Exhibit 117: AbbVie Inc. - Product / Service
Exhibit 118: AbbVie Inc. - Key news
Exhibit 119: AbbVie Inc. - Key offerings
12.5 Alkem Laboratories Ltd.
Exhibit 120: Alkem Laboratories Ltd. - Overview
Exhibit 121: Alkem Laboratories Ltd. - Business segments
Exhibit 122: Alkem Laboratories Ltd. - Key news
Exhibit 123: Alkem Laboratories Ltd. - Key offerings
Exhibit 124: Alkem Laboratories Ltd. - Segment focus
12.6 Eli Lilly and Co.
Exhibit 125: Eli Lilly and Co. - Overview
Exhibit 126: Eli Lilly and Co. - Product / Service
Exhibit 127: Eli Lilly and Co. - Key news
Exhibit 128: Eli Lilly and Co. - Key offerings
12.7 GENFIT SA
Exhibit 129: GENFIT SA - Overview
Exhibit 130: GENFIT SA - Product / Service
Exhibit 131: GENFIT SA - Key offerings
12.8 Glenmark Pharmaceuticals Ltd.
Exhibit 132: Glenmark Pharmaceuticals Ltd. - Overview
Exhibit 133: Glenmark Pharmaceuticals Ltd. - Product / Service
Exhibit 134: Glenmark Pharmaceuticals Ltd. - Key offerings
12.9 ICE S.p.a.
Exhibit 135: ICE S.p.a. - Overview
Exhibit 136: ICE S.p.a. - Product / Service
Exhibit 137: ICE S.p.a. - Key offerings
12.10 Intercept Pharmaceuticals Inc.
Exhibit 138: Intercept Pharmaceuticals Inc. - Overview
Exhibit 139: Intercept Pharmaceuticals Inc. - Product / Service
Exhibit 140: Intercept Pharmaceuticals Inc. - Key offerings
12.11 Ipsen Pharma
Exhibit 141: Ipsen Pharma - Overview
Exhibit 142: Ipsen Pharma - Business segments
Exhibit 143: Ipsen Pharma - Key offerings
Exhibit 144: Ipsen Pharma - Segment focus
12.12 Leeford Healthcare Ltd.
Exhibit 145: Leeford Healthcare Ltd. - Overview
Exhibit 146: Leeford Healthcare Ltd. - Key offerings
12.13 NGM Biopharmaceuticals Inc.
Exhibit 147: NGM Biopharmaceuticals Inc. - Overview
Exhibit 148: NGM Biopharmaceuticals Inc. - Key offerings
12.14 Novartis AG
Exhibit 149: Novartis AG - Overview
Exhibit 150: Novartis AG - Business segments
Exhibit 151: Novartis AG - Key offerings
Exhibit 152: Novartis AG - Segment focus
12.15 Teva Pharmaceutical Industries Ltd.
Exhibit 153: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 154: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 155: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 156: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 157: Teva Pharmaceutical Industries Ltd. - Segment focus
12.16 Viatris Inc.
Exhibit 158: Viatris Inc. - Overview
Exhibit 159: Viatris Inc. - Business segments
Exhibit 160: Viatris Inc. - Key news
Exhibit 161: Viatris Inc. - Key offerings
Exhibit 162: Viatris Inc. - Segment focus
12.17 Zydus Lifesciences Ltd.
Exhibit 163: Zydus Lifesciences Ltd. - Overview
Exhibit 164: Zydus Lifesciences Ltd. - Business segments
Exhibit 165: Zydus Lifesciences Ltd. - Key offerings
Exhibit 166: Zydus Lifesciences Ltd. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 167: Inclusions checklist
Exhibit 168: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 169: Currency conversion rates for US$
13.4 Research methodology
Exhibit 170: Research methodology
Exhibit 171: Validation techniques employed for market sizing
Exhibit 172: Information sources
13.5 List of abbreviations
Exhibit 173: List of abbreviations